NI201900077A - Inhibidores selectivos de jak1 - Google Patents
Inhibidores selectivos de jak1Info
- Publication number
- NI201900077A NI201900077A NI201900077A NI201900077A NI201900077A NI 201900077 A NI201900077 A NI 201900077A NI 201900077 A NI201900077 A NI 201900077A NI 201900077 A NI201900077 A NI 201900077A NI 201900077 A NI201900077 A NI 201900077A
- Authority
- NI
- Nicaragua
- Prior art keywords
- selective inhibitors
- jak1 selective
- compounds
- formula
- disclosed
- Prior art date
Links
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 title 1
- 229940124639 Selective inhibitor Drugs 0.000 title 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se desvelan en el presente documento compuestos de fórmula (I), y sales farmacéuticamente aceptables de los mismos, en la que R1-R8 tienen cualquiera de los significados definidos en el presente documento. Además, se desvelan composiciones farmacéuticas que comprenden compuestos de Fórmula (I) y métodos de uso de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762447057P | 2017-01-17 | 2017-01-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI201900077A true NI201900077A (es) | 2020-03-18 |
Family
ID=61024756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI201900077A NI201900077A (es) | 2017-01-17 | 2019-07-17 | Inhibidores selectivos de jak1 |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US10961228B2 (es) |
| EP (2) | EP3571192B1 (es) |
| JP (3) | JP6986086B2 (es) |
| KR (2) | KR102659213B1 (es) |
| CN (2) | CN110461830B (es) |
| AR (1) | AR110753A1 (es) |
| AU (1) | AU2018209667B2 (es) |
| BR (1) | BR112019014526A2 (es) |
| CA (1) | CA3049175A1 (es) |
| CL (1) | CL2019001993A1 (es) |
| CO (1) | CO2019007888A2 (es) |
| CR (1) | CR20190332A (es) |
| DK (1) | DK3571192T3 (es) |
| DO (1) | DOP2019000184A (es) |
| EA (1) | EA037067B1 (es) |
| EC (1) | ECSP19051352A (es) |
| ES (1) | ES2938648T3 (es) |
| FI (1) | FI3571192T3 (es) |
| HR (1) | HRP20230069T1 (es) |
| HU (1) | HUE061064T2 (es) |
| IL (1) | IL267851B (es) |
| JO (1) | JOP20190174B1 (es) |
| LT (1) | LT3571192T (es) |
| MA (1) | MA47301B1 (es) |
| MX (2) | MX2019008435A (es) |
| NI (1) | NI201900077A (es) |
| PE (1) | PE20191108A1 (es) |
| PH (1) | PH12019501639A1 (es) |
| PL (1) | PL3571192T3 (es) |
| PT (1) | PT3571192T (es) |
| RS (1) | RS63981B1 (es) |
| SG (1) | SG11201906222WA (es) |
| SI (1) | SI3571192T1 (es) |
| TW (1) | TWI753089B (es) |
| UA (1) | UA124246C2 (es) |
| WO (1) | WO2018134213A1 (es) |
| ZA (1) | ZA201906875B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018209667B2 (en) * | 2017-01-17 | 2020-05-07 | Astrazeneca Ab | JAK1 selective inhibitors |
| WO2018139903A1 (ko) | 2017-01-26 | 2018-08-02 | 한미약품 주식회사 | 피리미딘 화합물 및 그의 의약 용도 |
| SG11202100240RA (en) | 2018-07-18 | 2021-02-25 | Astrazeneca Ab | A xinafoate salt of a jak inhibiting compound |
| KR20210095621A (ko) * | 2018-09-21 | 2021-08-02 | 상하이 엔노바바이오 파마슈티컬스 씨오 엘티디. | 키나아제 억제 활성을 가진 방향족 헤테로고리 화합물 |
| KR20220003537A (ko) | 2019-04-19 | 2022-01-10 | 디잘 (지앙수) 파마슈티칼 씨오., 리미티드 | Jak1 선택적 키나제 억제제 |
| CA3174321A1 (en) * | 2020-04-09 | 2021-10-14 | Disarm Therapeutics, Inc. | Indazole derivatives as inhibitors of sarm1 |
| US20240025884A1 (en) * | 2022-07-05 | 2024-01-25 | Dong-A St Co., Ltd. | Compounds as gcn2 inhibitors, pharmaceutical compositions and uses thereof |
| CN115260128B (zh) * | 2022-09-21 | 2022-12-09 | 苏州凯瑞医药科技有限公司 | 一种新型jak抑制剂关键中间体的制备方法 |
| CN115974845A (zh) * | 2023-01-19 | 2023-04-18 | 奥锐特药业股份有限公司 | 奥希替尼中间体的制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070084067A (ko) * | 2004-10-13 | 2007-08-24 | 와이어쓰 | Ｎ-벤젠설포닐 치환 아닐리노-피리미딘 동족체 |
| CN101421250A (zh) * | 2006-01-30 | 2009-04-29 | 埃克塞里艾克西斯公司 | 作为jak-2调节剂的4-芳基-2-氨基-嘧啶或4-芳基-2-氨基烷基-嘧啶及包含它们的药物组合物 |
| WO2009046416A1 (en) * | 2007-10-05 | 2009-04-09 | Targegen Inc. | Anilinopyrimidines as jak kinase inhibitors |
| GB0805477D0 (en) * | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
| UA110324C2 (en) * | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| MX347851B (es) | 2010-03-10 | 2017-05-16 | Incyte Corp | Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1). |
| CN103209695A (zh) * | 2010-09-15 | 2013-07-17 | 弗·哈夫曼-拉罗切有限公司 | 氮杂苯并噻唑化合物、组合物及应用方法 |
| WO2015061665A1 (en) | 2013-10-24 | 2015-04-30 | Abbvie Inc. | Jak1 selective inhibitor and uses thereof |
| EP4219482A1 (en) * | 2015-09-25 | 2023-08-02 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Compounds and methods for inhibiting jak |
| AU2018209667B2 (en) * | 2017-01-17 | 2020-05-07 | Astrazeneca Ab | JAK1 selective inhibitors |
-
2018
- 2018-01-16 AU AU2018209667A patent/AU2018209667B2/en active Active
- 2018-01-16 LT LTEPPCT/EP2018/051038T patent/LT3571192T/lt unknown
- 2018-01-16 KR KR1020237032917A patent/KR102659213B1/ko active IP Right Grant
- 2018-01-16 HR HRP20230069TT patent/HRP20230069T1/hr unknown
- 2018-01-16 PE PE2019001401A patent/PE20191108A1/es unknown
- 2018-01-16 ES ES18701296T patent/ES2938648T3/es active Active
- 2018-01-16 CN CN201880018044.3A patent/CN110461830B/zh active Active
- 2018-01-16 BR BR112019014526-5A patent/BR112019014526A2/pt active Search and Examination
- 2018-01-16 MX MX2019008435A patent/MX2019008435A/es unknown
- 2018-01-16 PT PT187012968T patent/PT3571192T/pt unknown
- 2018-01-16 CN CN202211243959.9A patent/CN115925693A/zh active Pending
- 2018-01-16 KR KR1020197023855A patent/KR102585048B1/ko active IP Right Grant
- 2018-01-16 EP EP18701296.8A patent/EP3571192B1/en active Active
- 2018-01-16 CA CA3049175A patent/CA3049175A1/en active Pending
- 2018-01-16 SG SG11201906222WA patent/SG11201906222WA/en unknown
- 2018-01-16 JO JOP/2019/0174A patent/JOP20190174B1/ar active
- 2018-01-16 US US16/478,168 patent/US10961228B2/en active Active
- 2018-01-16 HU HUE18701296A patent/HUE061064T2/hu unknown
- 2018-01-16 PL PL18701296.8T patent/PL3571192T3/pl unknown
- 2018-01-16 MA MA47301A patent/MA47301B1/fr unknown
- 2018-01-16 EP EP22209765.1A patent/EP4219470A1/en active Pending
- 2018-01-16 EA EA201991700A patent/EA037067B1/ru unknown
- 2018-01-16 WO PCT/EP2018/051038 patent/WO2018134213A1/en unknown
- 2018-01-16 FI FIEP18701296.8T patent/FI3571192T3/fi active
- 2018-01-16 SI SI201830849T patent/SI3571192T1/sl unknown
- 2018-01-16 JP JP2019537377A patent/JP6986086B2/ja active Active
- 2018-01-16 RS RS20230130A patent/RS63981B1/sr unknown
- 2018-01-16 DK DK18701296.8T patent/DK3571192T3/da active
- 2018-01-16 CR CR20190332A patent/CR20190332A/es unknown
- 2018-01-16 UA UAA201909176A patent/UA124246C2/uk unknown
- 2018-01-17 TW TW107101685A patent/TWI753089B/zh active
- 2018-01-17 AR ARP180100104A patent/AR110753A1/es unknown
-
2019
- 2019-07-04 IL IL267851A patent/IL267851B/en unknown
- 2019-07-15 MX MX2022002976A patent/MX2022002976A/es unknown
- 2019-07-15 PH PH12019501639A patent/PH12019501639A1/en unknown
- 2019-07-15 CL CL2019001993A patent/CL2019001993A1/es unknown
- 2019-07-17 EC ECSENADI201951352A patent/ECSP19051352A/es unknown
- 2019-07-17 DO DO2019000184A patent/DOP2019000184A/es unknown
- 2019-07-17 NI NI201900077A patent/NI201900077A/es unknown
- 2019-07-23 CO CONC2019/0007888A patent/CO2019007888A2/es unknown
- 2019-10-18 ZA ZA2019/06875A patent/ZA201906875B/en unknown
-
2021
- 2021-03-01 US US17/188,097 patent/US11897869B2/en active Active
- 2021-11-26 JP JP2021191658A patent/JP7394820B2/ja active Active
-
2023
- 2023-10-20 JP JP2023180744A patent/JP2024010041A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2019000184A (es) | Inhibidores selectivos de jak1 | |
| CL2020000075A1 (es) | Carboxamidas como moduladores de los canales de sodio. | |
| CO2020007244A2 (es) | Inhibidores de kras g12c | |
| CL2017000902A1 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| UY37205A (es) | Inhibidores de bromodominios | |
| CL2018001899A1 (es) | Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock) | |
| SV2018005687A (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer | |
| CR20170116A (es) | Compuestos que inhiben la proteina mcl-1 | |
| UY35834A (es) | Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon | |
| CL2017000820A1 (es) | Compuestos de aminopurina sustituida, composiciones de los mismos, y metodos de tratamiento con los mismos | |
| NI201500119A (es) | Compuestos de heteroarilo y sus usos | |
| CR20180072A (es) | Nuevos compuestos biciclicos como inhibidores de atx | |
| GT201700023A (es) | Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias | |
| CR20170003A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| DOP2015000170A (es) | Compuestos químicos | |
| CL2019001694A1 (es) | Compuestos de pirazolopirimidina y métodos de uso de los mismos. | |
| ECSP17069696A (es) | Compuestos novedosos | |
| CO2020004977A2 (es) | Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa | |
| CR20160070A (es) | Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos | |
| CO2020007895A2 (es) | Inhibidores de histona acetiltransferasa de la familia myst | |
| CY1122423T1 (el) | Παραγωγα πυριμιδινης χρησιμα ως εκλεκτικοι αναστολεις jak3 kai/ή jak1 | |
| DOP2018000066A (es) | Compuestos útiles para inhibir ror-gamma-t | |
| GT201300225A (es) | Tieno (2,3-d) derivados de pirimidina y su uso para el tratamiento de la arritmia | |
| ECSP18056196A (es) | Derivados de indano | |
| UY36958A (es) | Compuestos para administración intracelular |